Leukemia Research
Volume 30, Issue 2 , Pages 190-203 , February 2006

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing

  • H.B. Koon

      Affiliations

    • Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    • ,
  • P. Severy

      Affiliations

    • Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    • ,
  • D.S. Hagg

      Affiliations

    • Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    • ,
  • K. Butler

      Affiliations

    • Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    • ,
  • T. Hill

      Affiliations

    • Division of Nuclear Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    • ,
  • A.G. Jones

      Affiliations

    • Division of Nuclear Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    • ,
  • T.A. Waldmann

      Affiliations

    • Metabolism Branch, National Cancer Institute, National Institutes of Heath, Bethesda, MD, USA
    • ,
  • R.P. Junghans

      Affiliations

    • Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Present address: Department of Surgery, Roger Williams Medical Center, 825 Chalkstone Avenue, Providence, RI 02908, USA. Tel.: +1 401 456 2507; fax: +1 401 456 4812.

Received 11 March 2005 ,Accepted 16 June 2005.

References 

  1. Waldmann TA, Pastan IH, Gansow OA, Junghans RP. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med. 1992;116:148–160
  2. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA. 1989;86:10029–10033
  3. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990;50:1495–1502
  4. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701–1712
  5. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063–4075
  6. Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol. 1998;44:942–947
  7. Carpenter CB, Kirkman RL, Shapiro ME, Milford EL, Tiney NL, Waldmann TA, et al. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation. Am J Kidney Dis. 1989;14:54–57
  8. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338:161–165
  9. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res. 1989;49:2639–2644
  10. Kozak RW, Fitzgerald DP, Atcher RW, Goldman CK, Nelson DL, Gansow OA, et al. Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. J Immunol. 1990;144:3417–3423
  11. Hagg DS, Junghans RP. Measurement and biological correlates of antibody bioactivity during antibody immunotherapies. J Immunol Methods. 1998;219:7–21
  12. Junghans RP. The Brambell receptor (FcRB) and the biological half-life of clinical antibodies. Blood Bone Mar Transpl. 1999;9:667–679
  13. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673–680
  14. Junghans RP. Leukemia is a disease of the marrow. Images in Clinical Medicine. N Engl J Med. 1998;339:1375
  15. Junghans RP, Carrasquillo JA, Waldmann TA. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. Proc Natl Acad Sci USA. 1998;95:1752–1757
  16. Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 1996;183:1587–1602
  17. Junghans RP, Stone A, Lewis MS. Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac): evidence for a monomeric structure. J Biol Chem. 1996;271:10453–10460
  18. Scheinberg DB, Sgouros G, Junghans RP. Antibody-based immunotherapies for cancer. In:  Chabner BA,  Longo DL editor. Cancer chemotherapy and biotherapy: principles and practice. 3rd ed.. Philadelphia: Lippincott; 2001;p. 850–890[chapter 29]
  19. Junghans RP. A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays. Cancer Immunol Immunother. 1990;31:207–212
  20. Waldmann TA, Goldman C, Top L, Grant A, Burton J, Bamford R, et al. The interleukin-2 receptor: a target for immunotherapy. Adv Exp Med Biol. 1992;323:57–66
  21. Junghans RP, Ahn YS. High-dose intravenous gamma globulin to suppress alloimmune destruction of donor platelets. Am J Med. 1984;76:204–208
  22. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431–1439
  23. Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA. 1991;88:2663–2667
  24. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904–914
  25. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991;78:2411–2418
  26. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333

PII: S0145-2126(05)00224-9

doi: 10.1016/j.leukres.2005.06.007

Leukemia Research
Volume 30, Issue 2 , Pages 190-203 , February 2006

Article Tools

* Image Usage & Resolution